This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Prevalence of Lymphoma in IBD

This study has been completed.
Information provided by (Responsible Party):
Indiana University Identifier:
First received: December 19, 2007
Last updated: August 7, 2015
Last verified: August 2015
Patients with inflammatory bowel disease (IBD) may be at increased risk of lymphoma. The majority of lymphomas in patients with IBD occur in areas of active inflammation. The relationship between IBD and lymphoproliferative disease is however unclear, since both chronic inflammation as well as medications used to treat IBD (especially immunosuppressives - Azathioprine or 6-MP - and anti-TNF alpha agents) have been associated with increased risk of lymphoma. We plan to study the association between IBD and lymphoma in a large, mixed, community based and referral population from the IBD database at Indiana University.

Lymphoma Inflammatory Bowel Disease

Study Type: Observational
Study Design: Observational Model: Case Control
Time Perspective: Retrospective
Official Title: Prevalence and Risk Factor for Lymphoproliferative Disease in Patients With Inflammatory Bowel Disease

Resource links provided by NLM:

Further study details as provided by Indiana University:

Enrollment: 7
Study Start Date: April 2006
Study Completion Date: October 2008
Primary Completion Date: October 2008 (Final data collection date for primary outcome measure)


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
Patients diagnosed with both Inflammatory bowel disease and lymphoma over the last 30 years.

Inclusion Criteria:

  • Inflammatory Bowel disease
  • Lymphoma
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00577538

United States, Indiana
Indiana University Medical Center
Indianapolis, Indiana, United States, 46202
Sponsors and Collaborators
Indiana University
Principal Investigator: Michael V. Chiorean, M.D. Indiana University
  More Information

Responsible Party: Indiana University Identifier: NCT00577538     History of Changes
Other Study ID Numbers: 060358
IRB# 0603-58
Study First Received: December 19, 2007
Last Updated: August 7, 2015

Additional relevant MeSH terms:
Intestinal Diseases
Inflammatory Bowel Diseases
Neoplasms by Histologic Type
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Gastrointestinal Diseases
Digestive System Diseases
Gastroenteritis processed this record on September 21, 2017